Sanofi American Depositary Receipt (SNY)
EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis
Sanofi wins EU nod for Cenrifki in secondary progressive multiple sclerosis without relapses, while Wayrilz gets Japan nod for immune thrombocytopenia.
Sanofi Multiple Sclerosis Drug Gets EU Approval
The authorization of Cenrifki for the treatment of secondary progressive multiple sclerosis without relapses follows a rejection from U.S. drug regulators.
Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?
SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.
Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First
Sanofi remains a compelling investment opportunity, driven by a robust pipeline and strong fundamentals. Sarclisa sales in Q1 of 2026 grew by 30.1% to $193.21 million; expansion with on-body injector [OBI] could make a push to compete in the MM space against Darzalex. Dupixent sales in Q1 of 2026 grew by 30.8% to $4.85 billion, boosted by continued strong execution and expansion for pediatric patients in CSU.
Sanofi Wins FDA Nod for Expanded Use of T1D Drug in Children
SNY wins FDA approval to expand Tzield's use in children with newly diagnosed stage 3 T1D, opening treatment to a broader patient group.
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
The U.S. Food and Drug Administration approved Sanofi's injection to slow the loss of the body's own insulin production in children aged 8 to 17 years recently diagnosed with stage 3 type 1 diabetes, the agency said on Friday.
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results
SNY halts its phase III MOBILIZE study after an interim review finds riliprubart unlikely to deliver sufficient efficacy in refractory CIDP patients.
Sanofi ends Phase 3 riliprubart trial after weak interim results
Biopharmaceutical company Sanofi will stop a Phase 3 trial of its drug riliprubart for a rare neurological condition after an interim analysis of the study found it unlikely to provide sufficient efficacy.
Sanofi to Stop Late-Stage Study of Immune-Disorder Drug
The termination is an early setback to new chief executive Belen Garijo, who took the helm last month.
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?
Sanofi shares slip despite strong growth. However, Dupixent, new launches, pipeline progress and a low valuation support staying invested.
FDA Grants Priority Review to SNY's Filing for Gaucher Disease Drug
Sanofi secures FDA priority review for venglustat in GD3, setting up a November decision on a potential first U.S. therapy for neurological symptoms.
